for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vermillion, Inc.

VRML.OQ

Latest Trade

0.87USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.36

 - 

1.57

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.87
Open
--
Volume
--
3M AVG Volume
2.57
Today's High
--
Today's Low
--
52 Week High
1.57
52 Week Low
0.36
Shares Out (MIL)
97.24
Market Cap (MIL)
80.99
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Vermillion Reports Third Quarter 2019 Financial Results

Vermillion Reports Q2 2019 Financial Results

Vermillion Inc Received A Deficiency Letter From Listing Qualifications Department Of Nasdaq Stock Market

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vermillion, Inc.

Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.

Contact Info

Suite 100

12117 Bee Caves Road Building Three

+1.512.5190400

http://www.vermillion.com

Executive Leadership

James T. LaFrance

Chairman of the Board

Valerie Barber Palmieri

President, Chief Executive Officer

Robert Harry Beechey

Chief Financial Officer

Donald G. Munroe

Senior Vice President - Business Development, Chief Scientific Officer

Chris Goulart

Senior Vice President - Commercial Operations

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
19.51
Price To Book (MRQ)
6.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.51
LT Debt To Equity (MRQ)
9.88
Return on Investment (TTM)
-122.02
Return on Equity (TTM)
-97.78

Latest News

Latest News

BRIEF-Vermillion Announces Pricing Of $15 Mln Concurrent Public Offerings Of Stock

* VERMILLION, INC. ANNOUNCES PRICING OF $15 MILLION CONCURRENT PUBLIC OFFERINGS OF COMMON STOCK AND PREFERRED STOCK

BRIEF-Vermillion Reports Qtrly Loss Per Share $0.05

* VERMILLION REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

BRIEF-Vermillion Announces Agreement With Bluecross Blueshield Of Illinois

* VERMILLION ANNOUNCES AGREEMENT WITH BLUECROSS BLUESHIELD OF ILLINOIS Source text for Eikon: Further company coverage:

BRIEF-Vermillion Appoints Bob Beechey To Newly Created CFO Post

* VERMILLION - MOST RECENTLY, BEECHEY WAS VICE PRESIDENT AND GENERAL MANAGER OF Q SQUARED SOLUTIONS BIOANALYTICAL, ADME LABORATORY OPERATIONS Source text for Eikon: Further company coverage:

BRIEF-Vermillion reports third quarter loss of $0.06 per share

* Qtrly net loss per share attributable to common stockholders basic and diluted $0.06 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Vermillion to report Q3 results on Nov 8

* Vermillion to report third quarter 2017 financial results and host investor conference call on November 8th Source text for Eikon: Further company coverage:

BRIEF-Vermillion files for mixed shelf of up to $50 mln - SEC filing

* Vermillion files for mixed shelf of up to $50 million - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Vermillion reports Q2 loss per share $0.04

* Q2 revenue rose 27 percent to $898,000 Source text for Eikon: Further company coverage:

BRIEF-Vermillion Q1 loss per share $0.05

* Q1 revenue $726,000 versus $505,000 Source text for Eikon: Further company coverage:

BRIEF-Vermillion files for resale of up to 6.6 mln shares of common stock

* Files for resale of up to 6.6 million shares of co's common stock - sec filing Source text - http://bit.ly/2oVnfQO Further company coverage:

BRIEF-Vermillion enters into a contract with TriCare South

* Aspira labs announces tricare south contract Source text for Eikon: Further company coverage:

BRIEF-Vermillion say co, unit entered amendment No. 2 to testing, services agreement with Quest Diagnostics effective March 11, 2017

* Vermillion - co, unit entered amendment no. 2 to testing and services agreement with quest diagnostics incorporated effective March 11, 2017

BRIEF-Vermillion attains out-of-state provider status with Medi-Cal

* Vermillion Inc - attained out-of-state provider status with Medi-Cal, California's medicaid program, for ova1 /multivariate index assay Source text for Eikon: Further company coverage:

BRIEF-Vermillion announces equity financing of $5.6 million

* Vermillion Inc - under terms of private placement,vermillion has agreed to sell 3.7 million shares of its common stock at price of $1.40 per share Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up